Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Those in prison are less healthy than the general population, are far more likely to have engaged in high-risk behaviors that can result in organ damage, disease and disability, and age more rapidly than nonincarcerated individuals do.
Giving undocumented immigrants and those with DACA status (DREAMers) access to health care and medical education enables them to contribute to these systems.
AMA J Ethics. 2017;19(3):221-233. doi:
10.1001/journalofethics.2017.19.3.peer1-1703.
Some commentators say comparative trials of FDA-approved drugs are overburdened by current Common Rule regulations and that researchers should not be required to obtain explicit consent for participation in the most innocuous of these trials.
As physicians we decide which tests or treatments go on the bill but have little idea how our decisions impact what patients pay. Now patients, payers, and policymakers are demanding that we consider the cost of our recommendations.